PRPO Stock — Precipio Inc

Precipio Inc (PRPO)

Updated October 16, 2026.

PRPO is a Stock. Total return is -100.0% over the past 26.2 years, 811.4 points behind SPY at 711.4%.

Precipio Inc is a healthcare biotechnology company that develops cancer diagnostic products and services, including HemeScreen genetic diagnostic panels for blood cancer testing and IV-Cell proprietary cell culture media for research applications, along with biomarker testing services for biopharmaceutical customers. The company does not currently distribute dividends. Precipio appeals to investors seeking exposure to the diagnostic biotechnology sector rather than current income.

PRPO performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 26.2 years, 811.4 points behind SPY at 711.4%. Over the past year its total return — price change plus distributions reinvested — is 14.6%. Its deepest 1-year drawdown was 34.5%.

PRPO key facts

Asset type

Stock

Asset class

Equity

Inception date

07/18/2000

Distribution frequency

None

Last close

$21.38 (as of 2026-10-16)

Market cap

$38,265,268

Average volume

95130.0

Payment date

04/29/2019

Beta

1.302

Payout ratio

0.0%

Forward P/E

15.4321

EPS

$-0.64

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PRPO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 34.5%.

Who may consider PRPO — and who may not

It is a weaker fit for investors who need monthly cash flow (PRPO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on PRPO

• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions